Finasteride PSA Test UAE: Why FinaLloyd Users Must Disclose Treatment

Finasteride can reduce the amount of prostate-specific antigen measured in the blood. This means a PSA result obtained while taking FinaLloyd Finasteride 1mg tablets may need to be interpreted differently from a result in a man who is not using a 5-alpha-reductase inhibitor.

Official finasteride 1mg labelling reports that mean PSA fell from 0.7ng/mL to 0.5ng/mL after 12 months in clinical studies involving men aged 18 to 41. A separate randomised trial in men aged 40 to 60 found median PSA reductions of approximately 40% in the 40–49 age group and 50% in the 50–60 group after 48 weeks of finasteride 1mg. These are group averages from defined study populations—not a prediction for every user. (DailyMed)

The correct action is not to stop treatment, skip tablets or alter the laboratory number yourself.

The correct action is:

Tell the healthcare professional that you use finasteride, state the strength, explain when you started it and allow the clinician to interpret the PSA result in context.

Direct Answer

Why should finasteride users mention treatment before a PSA test?

In a finasteride PSA test UAE context, disclosure matters because finasteride can lower PSA. When the clinician does not know about the medicine, a reduced result may be compared incorrectly with reference values intended for untreated men.

Before the blood sample or prostate assessment, provide:

• The medicine name.
• The strength shown on the physical label.
• The prescribed daily schedule.
• The date treatment began.
• Whether use has been continuous.
• Any recent interruption.
• Whether another finasteride or dutasteride product is used.
• Previous PSA results.
• Any relevant urinary or prostate symptoms.
• A photograph of the medicine label when the exact product is uncertain.

Should you stop FinaLloyd before a finasteride PSA test UAE appointment?

Not unless the prescribing or testing clinician specifically instructs you to do so. Stopping briefly does not create a reliable untreated baseline, and inconsistent use can make interpretation more difficult. Official labelling also notes that non-compliance can affect PSA results. (DailyMed)

Should you double your own PSA result?

No. Some finasteride guidance and research use adjustment approaches, especially after sustained therapy, but the appropriate interpretation depends on dose, duration, prior values, age, clinical context and the exact test. The doctor—not the patient, retailer or hair-loss blog—should decide whether and how an adjustment is made.

Finasteride PSA Test UAE: What You Need to Disclose

Use this exact medicine statement at the appointment:

“I use finasteride for hair loss. My tablet contains 1mg, I started it on [date], and I take it according to this prescription.”

Also disclose:

• Brand name: FinaLloyd, when applicable.
• Generic active ingredient: finasteride.
• Tablet strength: 1mg, if confirmed from the physical pack.
• Current dose: exactly as prescribed.
• Start date.
• Date of the last tablet.
• Missed or interrupted use.
• Previous finasteride use.
• Any topical finasteride.
• Any dutasteride.
• Supplements or medicines affecting hormone or prostate assessment.
• Previous prostate investigations.

Do not simply say:

“I take a hair tablet.”

For a finasteride PSA test UAE appointment, the clinician needs the active ingredient and strength

Bring the packaging

Take one of the following:

• Original box.
• Original bottle.
• Blister strip.
• Patient-information leaflet.
• Clear photograph of the front and back labels.
• Prescription record.

This is particularly important for FinaLloyd because the current online page contains a serious dosage contradiction that must be corrected before publication or purchase counselling.

What Is PSA?

In this finasteride PSA test UAE guide, PSA stands for prostate-specific antigen

It is a protein produced by prostate tissue. A PSA test measures its concentration in a blood sample.

PSA may be used as one part of:

• Prostate-cancer risk assessment.
• Investigation of prostate-related symptoms.
• Follow-up after a previous result.
• Monitoring after prostate treatment.
• A broader prostate examination.

PSA is not a standalone cancer diagnosis.

A result can be influenced by several factors, including:

• Age.
• Prostate size.
• Prostate inflammation.
• Infection.
• Recent procedures.
• Medicine use.
• Individual biological variation.

This article does not tell a reader whether they should be screened or what result is normal for them. Screening and follow-up decisions should be individualised by a qualified clinician.

Why Does Finasteride Lower PSA?

For finasteride PSA test UAE interpretation, it matters that finasteride inhibits 5-alpha-reductase, reducing conversion of testosterone into dihydrotestosterone, or DHT.

DHT affects prostate tissue as well as androgen-sensitive scalp follicles.

When finasteride changes androgen activity within the prostate, measured PSA may fall. The effect is therefore relevant even when finasteride was prescribed for androgenetic alopecia rather than urinary symptoms.

Simplified pathway

Testosterone

     │

     │  5-alpha-reductase

     ▼

Dihydrotestosterone

     │

     ├── Influences androgen-sensitive scalp follicles

     │

     └── Influences prostate tissue

Finasteride inhibits 5-alpha-reductase

     │

     ▼

DHT decreases

     │

     ▼

PSA may also decrease

The diagram explains the relationship conceptually. It does not calculate how much one individual’s PSA should change.

How Much Can Finasteride 1mg Lower PSA?

For finasteride PSA test UAE results, there is no single PSA-reduction percentage that applies to every user.

Official 1mg-label data

In studies involving men aged 18 to 41:

• Mean PSA at baseline: 0.7ng/mL.
• Mean PSA at month 12: 0.5ng/mL. (DailyMed)

That is a mean reduction of approximately 29%:

(0.7 − 0.5) ÷ 0.7 × 100

= approximately 28.6%

This calculation describes the difference between the reported study means. It does not mean that every man taking finasteride 1mg experiences a 28.6% reduction.

Randomised trial in men aged 40 to 60

After 48 weeks of 1mg finasteride:

• Men aged 40–49 had a median PSA decrease of 40%.
• Men aged 50–60 had a median PSA decrease of 50%. (DailyMed)

The study authors concluded that the existing PSA-adjustment recommendation used with 5mg finasteride should also be considered for men using 1mg for androgenetic alopecia.

Why the figures differ

Differences may relate to:

• Age.
• Baseline PSA.
• Study design.
• Duration.
• Average versus median reporting.
• Individual prostate biology.
• Adherence.
• Population characteristics.

Use these finasteride PSA test UAE figures to understand why disclosure matters—not to calculate a personal diagnosis.

Does a Lower PSA Mean Finasteride Has Hidden Cancer?

That wording is too simplistic.

Finasteride can reduce the measured PSA level, including in a person who has prostate cancer. This is why, during finasteride PSA test UAE interpretation, the clinician must know about treatment and interpret changes appropriately. Official labelling states that any confirmed rise from the lowest PSA reached during treatment may require evaluation, even when the value remains within a range considered normal for untreated men. (DailyMed)

A lower value does not automatically mean:

• Cancer is present.
• Cancer is absent.
• Finasteride has “masked” a dangerous condition.
• The test has become useless.
• The medicine must be stopped.

PSA can remain useful when:

• Medicine use is disclosed.
• Previous values are available.
• Duration and adherence are known.
• The clinician interprets the result in context.
• Changes from the treatment-period low point are considered.

What Is a PSA Baseline?

A baseline is a reference measurement obtained before, or at a clinically meaningful point near, the start of treatment.

For finasteride PSA test UAE monitoring, a baseline may help a clinician compare:

• PSA before finasteride.
• PSA after treatment begins.
• Changes over time.
• A later increase from the lowest value.

However, this article does not recommend a PSA test for every young man before starting finasteride.

Whether testing is appropriate depends on factors such as:

• Age.
• Personal history.
• Family history.
• Symptoms.
• Previous results.
• Local clinical guidance.
• The prescriber’s assessment.

If you already started finasteride without a baseline

Do not stop treatment solely to create your own baseline.

Tell the clinician:

• When treatment began.
• Whether it has been continuous.
• Whether any earlier PSA result exists.
• Whether the dose changed.

The clinician can decide what information or follow-up is appropriate.

What Is the PSA Nadir?

The nadir is the lowest recorded PSA value during treatment.

Official finasteride 1mg labelling warns that any confirmed increase from the lowest value reached while on treatment may warrant evaluation, even when the absolute result remains within the usual range for untreated men. (DailyMed)

This is why serial records can matter in finasteride PSA test UAE interpretation.

A single laboratory number may be less informative than:

• Pre-treatment result.
• Treatment start date.
• Lowest treatment-period result.
• Current result.
• Whether tablets were taken consistently.
• Whether a repeat test confirms the change.

Do not determine your own nadir from screenshots without medical review.

Should Every PSA Result Be Multiplied by Two?

In a finasteride PSA test UAE setting, no patient should automatically multiply their own result and act on the calculation.

For men taking finasteride 5mg for six months or longer, official labelling commonly advises doubling an isolated PSA value for comparison with normal ranges in untreated men. A randomised study concluded that a similar adjustment principle should apply to men aged 40–60 taking finasteride 1mg for hair loss. (DailyMed)

However, interpretation can depend on:

• Finasteride dose.
• Duration.
• Age.
• Baseline value.
• Adherence.
• Trend over time.
• Laboratory method.
• Symptoms.
• Other medicines.
• Clinical examination.

Evidence-safe patient instruction

Do not alter the number yourself. Tell the clinician you take finasteride and ask how the reported value should be interpreted.

Why self-adjustment is risky

A patient may:

• Use the wrong multiplier.
• Apply it too early.
• Ignore a rise from the treatment-period nadir.
• Compare values from different laboratories incorrectly.
• Treat a screening threshold as a diagnosis.
• Delay follow-up.
• Become unnecessarily alarmed.

When Should You Mention Finasteride?

For a finasteride PSA test UAE appointment, mention finasteride use:

• When the PSA test is ordered.
• When booking the appointment.
• On the laboratory medicine form.
• Before the blood sample.
• During the doctor consultation.
• When a urologist reviews the result.
• When transferring care to another clinic.
• Before a prostate examination.
• Before repeating a previous PSA.
• When discussing urinary symptoms.

Do not assume the clinic can see every prescription purchased privately or online.

If you forgot to disclose it before the test

If finasteride was not disclosed before a finasteride PSA test UAE blood draw, tell the doctor as soon as possible.

Provide:

• Date of the test.
• Finasteride strength.
• Treatment start date.
• Current schedule.
• Any interruptions.
• Previous results.

The result may still be interpretable. The clinician will decide whether additional information or repeat testing is needed.

Should You Skip Finasteride on the Test Day?

No, unless the clinician has specifically directed you to do so.

Before a finasteride PSA test UAE appointment, skipping one tablet does not reliably remove finasteride’s biological effect on PSA.

It may instead create:

• Adherence uncertainty.
• Incorrect documentation.
• Confusion about the last dose.
• A temptation to stop for several days without advice.
• Difficulty comparing serial results.

Take the medicine according to the verified prescription and disclose it.

Should You Stop Finasteride for Several Weeks Before Testing?

Do not stop or restart a prescribed medicine independently.

A clinician considering interruption would need to decide:

• Whether stopping is medically necessary.
• How long an effect may persist.
• Whether a repeat test is required.
• What happens to hair-loss treatment.
• Whether restarting changes later interpretation.

A temporary pause does not automatically produce a valid untreated PSA baseline.

What Information Should Be Written on the Laboratory Request?

Where the form allows medicine information, include:

• Finasteride
• 1mg
• Used for androgenetic alopecia
• Started: [date]
• Current schedule: [as prescribed]

Where space is limited:

“Finasteride 1mg—hair loss—started [date].”

For finasteride PSA test UAE documentation, the patient should also tell the clinician verbally.

FinaLloyd Product-Page Verification

The live FinaLloyd Finasteride 1mg tablets page currently confirms:

• Product title: FinaLloyd Finasteride 1mg.
• Titanium-dioxide-free positioning.
• Each film-coated tablet contains finasteride 1mg.
• Pack options listed as 3 × 10 tablets and 10 × 10 tablets.
• A warning not to split or crush the tablets.
• A warning concerning handling by pregnant or potentially pregnant people.
• A direction to disclose finasteride before PSA screening.
• A reminder not to take two doses at once. (Hims N Hers FZ LLC)

Serious dosage error requiring correction

The same page currently says:

“For adult men, dosage is 1mg (2 tablets) of finasteride taken orally twice daily.”

This sentence is internally impossible because:

• The page says each tablet contains 1mg.
• Two tablets would therefore equal 2mg, not 1mg.
• Two tablets twice daily would total four 1mg tablets each day.
• Official finasteride 1mg hair-loss labelling states one 1mg tablet once daily. (himsnhers.ae)

Publication blocker

The current dosage sentence must be removed before:

• Publishing this article.
• Promoting the product.
• Sending dosage emails.
• Creating FAQ schema.
• Producing social-media copy.
• Giving customer-service instructions.

Recommended replacement webpage wording

Take FinaLloyd exactly as prescribed by your doctor and according to the licensed physical product leaflet. Do not take additional tablets after a missed dose unless specifically directed by a qualified healthcare professional.

The website should not publish a replacement numeric dose until the locally supplied product leaflet and authorised instructions have been verified.

Product-Name Consistency Issue

The product page title uses FinaLloyd, while sections of the copy refer to Finaroid and Lloyd Laboratories.

Before publication, verify:

• Exact brand name printed on the delivered pack.
• Manufacturer.
• Marketing-authorisation holder, where applicable.
• Country of manufacture.
• Tablet strength.
• Pack count.
• Licensed leaflet.
• Batch and expiry.

Do not assume that FinaLloyd and Finaroid are interchangeable names without packaging confirmation.

What the Physical FinaLloyd Label Must Confirm

Product identity

• Exact brand name.
• Finasteride 1mg per tablet.
• Manufacturer.
• Pack quantity.
• Batch number.
• Expiry date.

Dose

• Prescribed tablet count.
• Frequency.
• With-food or without-food instructions.
• Missed-dose instructions.
• Maximum daily amount.
• Whether tablets may be divided.

PSA and prostate information

• PSA disclosure warning.
• Prostate-screening wording.
• Advice about changes in PSA.
• Relevant monitoring information.

Safety

• Sexual adverse effects.
• Mood and depression warning.
• Suicidal-thought warning.
• Fertility information.
• Breast-symptom warning.
• Allergy warning.
• Pregnancy-handling warning.

Storage

• Temperature range.
• Moisture protection.
• Original-packaging requirement.
• Child-safety wording.

When the website, prescription and physical leaflet conflict, stop and contact Hims & Hers UAE before taking the product.

Does the PSA Warning Apply Only to 5mg Finasteride?

No.

The PSA effect is often associated with finasteride 5mg because that dose is used for benign prostatic hyperplasia and is frequently prescribed to older men.

However:

• Official 1mg labelling reports a reduction in PSA in younger men.
• A randomised trial showed meaningful median PSA reductions in men aged 40–60 using 1mg for hair loss. (DailyMed)

A man preparing for a finasteride PSA test UAE assessment while taking 1mg for androgenetic alopecia should therefore not assume:

“My dose is only for hair, so it cannot affect a prostate blood test.”

Does the PSA Warning Apply to Topical Finasteride?

The best-established PSA data involve oral finasteride.

Topical-finasteride exposure depends on:

• Concentration.
• Volume applied.
• Vehicle.
• Scalp area.
• Frequency.
• Skin condition.
• Product formulation.

For finasteride PSA test UAE interpretation, a person using FIN25 topical finasteride solution or another finasteride-containing topical should still disclose it.

The clinician can decide whether the topical exposure is relevant.

Do not assume that topical application has no systemic or laboratory implications.

What About Dutasteride?

Dutasteride is another 5-alpha-reductase inhibitor and can also affect PSA interpretation.

Tell the clinician about:

• Oral dutasteride.
• Topical dutasteride.
• D5a.
• Combination products containing dutasteride.
• Previous dutasteride use.

This article does not provide a dutasteride adjustment rule.

The key patient action for finasteride PSA test UAE interpretation remains the same:

Disclose the medicine, strength, route, start date and adherence.

What If You Use More Than One DHT-Blocking Product?

For a finasteride PSA test UAE appointment, disclose every finasteride or dutasteride product.

Examples include:

• Oral finasteride plus topical finasteride.
• Finasteride plus dutasteride.
• FR12 plus oral finasteride.
• FR16 plus FinaLloyd.
• FIN25 plus FinaLloyd.
• A compounded product with an incomplete label.

Do not list only the product you consider “strongest.”

The clinician needs the complete exposure history.

Do not combine multiple finasteride or dutasteride treatments without qualified medical supervision.

PSA Testing and Finasteride Adherence

For finasteride PSA test UAE interpretation, official labelling states that non-compliance can affect PSA results. (DailyMed)

Tell the clinician if you:

• Frequently miss tablets.
• Stopped for several weeks.
• Restarted recently.
• Changed dose.
• Switched from 5mg to 1mg.
• Switched from oral to topical.
• Used another brand.
• Took an uncertain amount because of incorrect website directions.

Do not report “continuous use” when the history was inconsistent.

Accurate information is more valuable than appearing perfectly adherent.

Can Finasteride Affect PSA Even When It Is Not Working for Hair?

Yes.

In finasteride PSA test UAE counselling, hair response and PSA response should be treated as different outcomes.

A person may:

• See little visible hair improvement.
• Still experience DHT suppression.
• Still have a change in PSA.
• Still develop adverse effects.

Do not decide that PSA disclosure is unnecessary because the hairline has not improved.

Does a Stable PSA Exclude Prostate Cancer?

No.

In a finasteride PSA test UAE assessment, PSA is only one part of the broader clinical picture.

A clinician may also consider:

• Age.
• Family history.
• Symptoms.
• Previous results.
• Examination.
• Imaging.
• Repeat blood testing.
• Specialist referral.
• Other laboratory findings.

Finasteride users should not interpret a stable or low PSA as a guarantee that no prostate condition exists.

Does a Rising PSA While Taking Finasteride Matter?

Official 1mg labelling states that a confirmed rise from the lowest PSA reached during treatment may signal the need for evaluation, even when the result remains within the usual untreated reference range. (DailyMed)

In finasteride PSA test UAE interpretation, this does not mean every small fluctuation indicates cancer.

It means:

• The change should not be ignored.
• The result may need confirmation.
• Adherence should be checked.
• The clinician should interpret the trend.
• Further evaluation may be appropriate.

Do not wait for the number to exceed an online threshold before informing the doctor.

What If Two Laboratories Give Different Results?

Differences may occur because of:

• Laboratory methods.
• Timing.
• Biological variation.
• Infection or inflammation.
• Medicine adherence.
• Recent procedures.
• Sample handling.

For finasteride PSA test UAE follow-up, provide both laboratory results to the clinician.

Whenever possible, retain:

• Laboratory name.
• Date.
• Exact PSA value.
• Units.
• Reference range.
• Finasteride status at the time.
• Medicine start date.

Do not compare screenshots without checking units.

Finasteride and Prostate Symptoms

Do not wait for a scheduled screening appointment when you develop concerning or persistent symptoms.

Seek medical assessment for symptoms such as:

• Difficulty passing urine.
• Inability to urinate.
• Blood in urine.
• Painful urination.
• Persistent pelvic discomfort.
• Unexplained worsening urinary symptoms.
• Any symptom the clinician considers urgent.

These symptoms do not diagnose cancer and may have many causes.

They require assessment rather than online PSA calculation.

Current Finasteride Safety Update

In May 2026, the UK Medicines and Healthcare products Regulatory Agency strengthened warnings relating to finasteride and dutasteride.

The updated advice states that finasteride is associated with:

• Low mood.
• Depression.
• Suicidal thoughts.
• Decreased sexual desire.
• Erectile dysfunction.
• Ejaculation problems.
• Sexual dysfunction that may persist after treatment is stopped.

The MHRA advises that people using finasteride 1mg should stop treatment and contact their healthcare professional promptly if they develop depression or suicidal thoughts. Anyone at immediate risk of self-harm should seek emergency help. (GOV.UK)

This safety information is separate from PSA interpretation, but it belongs in any responsible finasteride-patient guide.

Sexual, Fertility and Breast Symptoms

Official finasteride labelling and regulatory safety information include concerns involving:

• Reduced libido.
• Erectile dysfunction.
• Ejaculation changes.
• Testicular pain.
• Fertility or semen-quality concerns.
• Breast tenderness.
• Breast enlargement.
• Breast lumps or nipple discharge.
• Allergic reactions.

Report new or persistent symptoms to a qualified healthcare professional.

Do not continue or stop treatment solely on advice from social-media comments.

Pregnancy-Handling Precautions

Finasteride is not intended for use during pregnancy.

Official labelling states that pregnant or potentially pregnant individuals should not handle crushed or broken finasteride tablets because the active medicine may be absorbed through the skin and may harm development of a male fetus.

Intact coated tablets reduce contact during normal handling, provided they are not broken or crushed. (DailyMed)

Safe household handling

• Keep tablets intact.
• Do not crush them.
• Do not split them unless the authorised leaflet explicitly permits it.
• Keep them in original packaging.
• Store them away from children.
• Clean up broken-tablet powder carefully.
• Wash exposed skin with soap and water.
• Seek professional advice after meaningful pregnancy exposure.

The current FinaLloyd page also instructs users not to split or crush the tablets. (Hims N Hers FZ LLC)

UAE PSA Appointment Checklist

Before the finasteride PSA test UAE appointment

• Find the FinaLloyd package.
• Photograph the label.
• Record the treatment start date.
• Write down the prescribed schedule.
• List missed or interrupted use.
• Find previous PSA results.
• List topical finasteride or dutasteride.
• List other medicines and supplements.
• Write down relevant symptoms.
• Do not stop treatment independently.

At the clinic

• Say “I take finasteride 1mg for hair loss.”
• Show the label.
• State when treatment started.
• State whether use has been continuous.
• Ask whether the medicine is documented on the request form.
• Ask how the result will be interpreted.
• Do not request that the laboratory alter the result itself.

After the result

• Review the result with a clinician.
• Compare with previous values where available.
• Ask whether a repeat test is needed.
• Do not multiply the result independently.
• Do not stop finasteride based only on the number.
• Report new symptoms.
• Keep a copy for future comparison.

Doctor-Communication Card

Medicine: Finasteride

Brand: FinaLloyd

Strength: 1mg per tablet

Reason: Androgenetic alopecia

Started: [DD/MM/YYYY]

Prescribed schedule: [Insert]

Last dose: [Insert]

Interruptions or missed use: [Insert]

Other finasteride/dutasteride products: [Insert]

Previous PSA result and date: [Insert]

Keep this information on your phone or with the medicine list.

What Not to Do Before a PSA Test

Do not:

• Hide finasteride use because it is “only for hair.”
• Stop tablets without advice.
• Skip only the test-day tablet.
• Double your laboratory result yourself.
• Compare the result with another person’s number.
• Use a generic online calculator as a diagnosis.
• Take extra finasteride after a missed dose.
• Follow the current incorrect FinaLloyd webpage dosage.
• Assume a low result means no prostate risk.
• Ignore a confirmed rise from the treatment-period low point.
• Forget to mention topical finasteride or dutasteride.
• Throw away previous PSA reports.
• Change dose to manipulate the blood test.

Product-Page Corrections Required Before Publishing

Correction 1: Dosage

Remove:

“1mg (2 tablets) twice daily.”

Replace it with verified, locally authorised wording from the physical leaflet and prescriber.

Correction 2: Brand naming

Clarify whether the product is:

• FinaLloyd.
• Finaroid.
• Another Lloyd Laboratories brand.

Use one verified name consistently.

Correction 3: PSA warning

Keep the disclosure warning but expand it to state:

• Finasteride may lower PSA.
• Treatment start date and adherence should be disclosed.
• The patient should not adjust the result independently.
• A confirmed rise from the treatment-period low value may require evaluation.

Correction 4: Current safety information

Add up-to-date warnings about:

• Depression.
• Suicidal thoughts.
• Sexual dysfunction.
• Persistent sexual symptoms.
• Fertility concerns.
• Breast symptoms.
• Pregnancy handling.

Correction 5: Missed dose

Use the licensed leaflet’s exact instruction.

The page currently says to take the tablet as soon as remembered and not take two doses at once. This must be checked against the local supplied leaflet before publication.

Evidence Hierarchy

Level 1 — Official finasteride 1mg labelling

Supports:

• PSA reduction in younger men.
• Need for adjusted interpretation.
• Importance of a rise from the treatment-period nadir.
• Impact of non-compliance.
• Pregnancy-handling precautions. (DailyMed)

Level 2 — Randomised PSA trial

Shows that 1mg finasteride significantly reduced PSA in men aged 40–60 after 48 weeks and supports adjustment of screening interpretation. (PubMed)

Level 3 — Current regulator safety guidance

Provides updated 2026 warnings concerning psychiatric symptoms, suicidal thoughts, and sexual dysfunction. (GOV.UK)

Level 4 — FinaLloyd product information

Confirms:

• Finasteride 1mg per tablet.
• PSA-disclosure wording.
• Tablet-handling warnings.
• Listed pack variants.

The webpage currently contains a serious dosage contradiction and cannot be treated as a reliable dose source until corrected. (Hims N Hers FZ LLC)

Level 5 — Patient-specific interpretation

Only the treating clinician can integrate:

• Actual result.
• Age.
• Baseline.
• Duration.
• Adherence.
• Symptoms.
• Family history.
• Examination.
• Other medicines.

Manufacturer Claims Versus Evidence

Buyer and User Decision Checklist

Before using FinaLloyd, confirm:

• Androgenetic alopecia has been assessed.
• The physical tablet contains finasteride 1mg.
• The locally authorised dose is clear.
• The online dosage error has not been followed.
• The patient-information leaflet is available.
• Sexual and psychiatric risks have been reviewed.
• Fertility plans have been discussed where relevant.
• Pregnancy-handling precautions can be followed.
• Any planned PSA or prostate assessment has been disclosed.
• Previous PSA results are retained.
• Other finasteride and dutasteride products are listed.
• The medicine will not be stopped or doubled independently.
• A clinician or pharmacist is available for questions.

Final Verdict: What Should a FinaLloyd User Do Before a PSA Test?

Before a finasteride PSA test UAE appointment:

1. Continue the prescribed medicine unless the clinician says otherwise.
2. Tell the doctor and laboratory that you use finasteride.
3. State that the tablet contains 1mg.
4. Give the treatment start date.
5. Disclose missed or interrupted use.
6. Mention topical finasteride and dutasteride products.
7. Provide previous PSA results.
8. Do not adjust the laboratory value yourself.
9. Review the result with a qualified clinician.
10. Report a confirmed rise or concerning symptoms promptly.

Finasteride 1mg can lower PSA meaningfully. Official labelling reports a fall in mean PSA among younger men, while a randomised study found median reductions of 40% to 50% in men aged 40–60 after 48 weeks. Those results demonstrate why medicine disclosure is medically important, but they do not provide a universal personal adjustment formula. (DailyMed)

Review the live FinaLloyd Finasteride 1mg tablets page only for product identification—not for its current contradictory dose.

Readers can also review:

• FIN25 topical finasteride solution
• Other men’s hair-care products available in the UAE
• The complete range of hair-loss treatments available in the UAE
• Current ordering and delivery information in the Hims & Hers UAE FAQs

For a missing leaflet, unclear brand identity, incorrect dose, damaged pack or conflict between the website and physical label, contact Hims & Hers UAE before taking the medicine.

Frequently Asked Questions

Does finasteride affect a PSA test?

Yes. Finasteride can lower measured PSA and must be disclosed before the result is interpreted. (DailyMed)

Does finasteride 1mg lower PSA?

Yes. Official labelling reports a reduction in mean PSA in younger men, and a randomised study found median reductions of 40% to 50% in men aged 40–60 after 48 weeks. (DailyMed)

Why does a hair-loss medicine affect a prostate test?

Finasteride reduces DHT by inhibiting 5-alpha-reductase. DHT affects prostate tissue as well as androgen-sensitive scalp follicles.

Should I tell the laboratory that I take FinaLloyd?

Yes. Tell both the ordering clinician and the laboratory that you take finasteride 1mg for hair loss.

Should I stop finasteride before a PSA test?

Not unless the prescribing or testing clinician specifically instructs you to stop.

Should I skip finasteride on the morning of the test?

No. Skipping one dose does not create a reliable untreated PSA result and can make adherence information less accurate.

Should I double my PSA result?

Do not adjust the number yourself. A clinician should interpret the result using dose, duration, adherence, previous values and clinical context.

What information should I give my doctor?

Give the medicine name, strength, prescribed schedule, start date, adherence history, other DHT-blocking medicines and previous PSA results.

What if I forgot to mention finasteride before the blood test?

Tell the clinician as soon as possible. The result may still be usable when medicine history is considered.

What does PSA nadir mean?

It means the lowest PSA value recorded during treatment. A confirmed increase from that low point may require evaluation. (DailyMed)

Does a low PSA mean I do not have prostate cancer?

No. PSA is not a standalone diagnosis, and finasteride can lower the value.

Can prostate cancer still raise PSA while I take finasteride?

Yes. Official labelling says a confirmed rise from the treatment-period lowest value may be important even if the number remains within the usual untreated range. (DailyMed)

Does topical finasteride affect PSA?

The amount of systemic exposure varies by formulation. Disclose topical finasteride and let the clinician decide its relevance.

Should I disclose dutasteride before a PSA test?

Yes. Tell the clinician about every oral or topical 5-alpha-reductase inhibitor.

Is FinaLloyd’s current online dosage correct?

The current page is internally contradictory. It says each tablet contains 1mg but also refers to two tablets twice daily. That sentence must not be followed. (Hims N Hers FZ LLC)

What is the official reference dose for finasteride 1mg hair-loss tablets?

Official reference labelling states one 1mg tablet once daily, but users must follow their own verified local prescription and physical leaflet. (DailyMed)

Can I take extra tablets if I miss a dose?

Do not double the dose. Follow the licensed physical leaflet or ask a pharmacist.

Can pregnant women handle FinaLloyd tablets?

Pregnant or potentially pregnant individuals should not handle crushed or broken finasteride tablets. Intact coated tablets reduce exposure during ordinary handling. (DailyMed)

What mental-health symptoms are linked to finasteride?

Current regulatory guidance warns about low mood, depression and suicidal thoughts. Finasteride 1mg users who develop depression or suicidal thoughts should stop treatment and seek prompt medical advice. (GOV.UK)

Can finasteride cause sexual side effects?

Yes. Regulatory guidance includes reduced sexual desire, erectile dysfunction and ejaculation problems, which may persist after stopping in some reported cases. (GOV.UK)

Should I get a PSA test before starting finasteride?

Not every person automatically needs one. Age, symptoms, risk factors and medical history should guide the clinician’s decision.

Can I create a PSA baseline by stopping finasteride myself?

No. Do not stop treatment independently to manufacture an untreated baseline.

What should I bring to a PSA appointment?

Bring the medicine package or a clear photograph, start date, prescribed schedule, adherence history and previous PSA results.

Who should interpret my PSA result?

A qualified doctor or urologist familiar with your medicine history should interpret it.